About Albany Molecular Research (NASDAQ:AMRI)
Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:AMRI
- CUSIP: N/A
- Web: www.amriglobal.com
Capitalization:- Market Cap: $905.82 million
- Outstanding Shares: 41,666,000
Average Prices:- 50 Day Moving Avg: $21.72
- 200 Day Moving Avg: $18.41
- 52 Week Range: $13.01 - $22.17
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 17.67
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $680.81 million
- Price / Sales: 1.33
- Book Value: $7.61 per share
- Price / Book: 2.86
Profitability:- EBITDA: $73.33 million
- Net Margins: -5.93%
- Return on Equity: -13.39%
- Return on Assets: -3.42%
Debt:- Debt-to-Equity Ratio: 0.62%
- Current Ratio: 0.68%
- Quick Ratio: 0.37%
Misc:- Average Volume: 1.27 million shs.
- Beta: 1.15
- Short Ratio: 8.49
Frequently Asked Questions for Albany Molecular Research (NASDAQ:AMRI)
What is Albany Molecular Research's stock symbol?
Albany Molecular Research trades on the NASDAQ under the ticker symbol "AMRI."
How were Albany Molecular Research's earnings last quarter?
Albany Molecular Research, Inc. (NASDAQ:AMRI) issued its quarterly earnings data on Tuesday, May, 10th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by $0.14. The company earned $102.80 million during the quarter, compared to analysts' expectations of $107.20 million. Albany Molecular Research had a negative net margin of 5.93% and a negative return on equity of 13.39%. View Albany Molecular Research's Earnings History.
Where is Albany Molecular Research's stock going? Where will Albany Molecular Research's stock price be in 2017?
4 analysts have issued twelve-month target prices for Albany Molecular Research's stock. Their predictions range from $18.00 to $18.00. On average, they anticipate Albany Molecular Research's stock price to reach $18.00 in the next year. View Analyst Ratings for Albany Molecular Research.
Who are some of Albany Molecular Research's key competitors?
Some companies that are related to Albany Molecular Research include Immunomedics (IMMU), Spectrum Pharmaceuticals (SPPI), Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Genus plc (GNS), Medpace Holdings (MEDP), Genomic Health (GHDX), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Cellectis S.A. (CLLS), Esperion Therapeutics (ESPR), Momenta Pharmaceuticals (MNTA), Arena Pharmaceuticals (ARNA), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Enanta Pharmaceuticals (ENTA), Abeona Therapeutics (ABEO), Heron Therapeutics (HRTX) and CRISPR THERAPTC (CRSP).
Who are Albany Molecular Research's key executives?
Albany Molecular Research's management team includes the folowing people:
- William S. Marth, President, Chief Executive Officer, Director
- Felicia Ladin, Chief Financial Officer, Senior Vice President, Treasurer
- Lori M. Henderson Esq., Senior Vice President, General Counsel, Secretary
- Christopher M Conway, Senior Vice President - Discovery and Development and Global Commercial Sales
- Milton Boyer, Senior Vice President - Drug Product Manufacturing
- Steven R. Hagen Ph.D., Senior Vice President - Manufacturing and Pharmaceuticals
- George Svokos, Chief Commercial Officer and Senior Vice President, API
- Jimmy Wang Ph.D., Chief Information Officer
- Thomas E. D' Ambra Ph.D., Non-Executive Chairman of the Board
- David H. Deming, Director
How do I buy Albany Molecular Research stock?
Shares of Albany Molecular Research can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Albany Molecular Research's stock price today?
One share of Albany Molecular Research stock can currently be purchased for approximately $21.74.
MarketBeat Community Rating for Albany Molecular Research (NASDAQ AMRI)MarketBeat's community ratings are surveys of what our community members think about Albany Molecular Research and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Albany Molecular Research (NASDAQ:AMRI)Earnings History by Quarter for Albany Molecular Research (NASDAQ AMRI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | $0.12 | $0.13 | $161.43 million | $163.80 million | View | Listen |  |
| 2/21/2017 | Q416 | $0.48 | $0.34 | $221.30 million | $191.30 million | View | Listen | |
| 11/8/2016 | Q316 | $0.13 | $0.17 | $160.75 million | $151.70 million | View | Listen | |
| 5/10/2016 | Q1 | $0.21 | $0.07 | $107.20 million | $102.80 million | View | Listen | |
| 2/17/2016 | Q415 | $0.36 | $0.40 | $133.40 million | $126.40 million | View | Listen | |
| 11/5/2015 | Q315 | $0.11 | $0.11 | $95.15 million | $101.40 million | View | Listen | |
| 8/4/2015 | Q215 | $0.18 | $0.19 | $85.00 million | $85.20 million | View | Listen | |
| 5/5/2015 | Q115 | $0.15 | $0.20 | $81.50 million | $75.10 million | View | N/A | |
| 2/12/2015 | Q414 | $0.33 | $0.28 | $91.90 million | $86.60 million | View | N/A | |
| 11/5/2014 | Q3 2014 | $0.16 | ($0.02) | $71.00 million | $62.47 million | View | N/A | |
| 8/5/2014 | Q214 | $0.20 | $0.22 | $65.64 million | $68.20 million | View | N/A | |
| 5/6/2014 | Q114 | $0.23 | $0.16 | $62.19 million | $51.00 million | View | N/A | |
| 2/12/2014 | Q4 | $0.17 | $0.22 | | | View | N/A | |
| 11/6/2013 | Q313 | $0.11 | $0.13 | $62.10 million | $53.00 million | View | N/A | |
| 8/6/2013 | Q2 2013 | | $0.12 | $50.00 million | $59.30 million | View | N/A | |
| 5/7/2013 | Q1 2013 | $0.10 | $0.23 | $53.70 million | $59.40 million | View | N/A | |
| 2/12/2013 | Q4 2012 | $0.09 | $0.17 | $56.49 million | $59.10 million | View | N/A | |
| 8/1/2012 | | $0.02 | $0.01 | | | View | N/A | |
| 5/9/2012 | | $0.05 | $0.02 | | | View | N/A | |
| 2/7/2012 | | ($0.12) | ($0.19) | | | View | N/A | |
| 11/8/2011 | | ($0.05) | ($0.19) | | | View | N/A | |
| 8/8/2011 | | ($0.03) | ($0.02) | | | View | N/A | |
| 5/4/2011 | | ($0.14) | ($0.02) | | | View | N/A | |
| 2/7/2011 | | ($0.15) | ($0.16) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Albany Molecular Research (NASDAQ:AMRI)2017 EPS Consensus Estimate: $1.02
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.11 | $0.11 | $0.11 |
| Q2 2017 | 2 | $0.23 | $0.28 | $0.26 |
| Q3 2017 | 2 | $0.15 | $0.19 | $0.17 |
| Q4 2017 | 2 | $0.42 | $0.54 | $0.48 |
| Q1 2018 | 1 | $0.22 | $0.22 | $0.22 |
(Data provided by Zacks Investment Research)
Dividend History for Albany Molecular Research (NASDAQ:AMRI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Albany Molecular Research (NASDAQ:AMRI)Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 72.10%
Insider Trades by Quarter for Albany Molecular Research (NASDAQ:AMRI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/2/2016 | Anthony J Maddaluna | Director | Buy | 1,518 | $16.46 | $24,986.28 | |
| 11/30/2016 | Steven R Hagen | SVP | Sell | 9,000 | $16.71 | $150,390.00 | |
| 11/16/2016 | Lori M Henderson | SVP | Sell | 6,000 | $17.00 | $102,000.00 | |
| 11/10/2016 | Steven R Hagen | SVP | Sell | 785 | $16.79 | $13,180.15 | |
| 8/9/2016 | Steven R Hagen | SVP | Sell | 1,401 | $15.29 | $21,421.29 | |
| 5/31/2016 | Kevin Oconnor | Director | Sell | 5,000 | $14.41 | $72,050.00 | |
| 5/16/2016 | William S Marth | CEO | Buy | 12,500 | $12.86 | $160,750.00 | |
| 5/13/2016 | George Svokos | COO | Buy | 12,500 | $12.82 | $160,250.00 | |
| 5/13/2016 | Steven R Hagen | SVP | Sell | 2,361 | $12.77 | $30,149.97 | |
| 11/9/2015 | Ambra Constance M D | Major Shareholder | Sell | 50,000 | $19.60 | $980,000.00 | |
| 8/17/2015 | Steven R Hagen | SVP | Sell | 1,000 | $20.45 | $20,450.00 | |
| 6/10/2015 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $19.77 | $395,400.00 | |
| 6/8/2015 | Steven R Hagen | SVP | Sell | 5,000 | $19.99 | $99,950.00 | |
| 6/4/2015 | William S Marth | CEO | Buy | 10,000 | $19.98 | $199,800.00 | |
| 6/1/2015 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $19.69 | $590,700.00 | |
| 5/11/2015 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $19.11 | $382,200.00 | |
| 5/8/2015 | Steven R Hagen | SVP | Sell | 14,500 | $19.27 | $279,415.00 | |
| 4/10/2015 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $18.50 | $370,000.00 | |
| 3/17/2015 | Steven R Hagen | SVP | Sell | 3,500 | $18.53 | $64,855.00 | |
| 3/12/2015 | Kevin Oconnor | Director | Sell | 5,000 | $18.22 | $91,100.00 | |
| 3/10/2015 | Ambra Thomas E Phd D | Director | Sell | 20,000 | $17.65 | $353,000.00 | |
| 3/10/2015 | George Svokos | Insider | Buy | 10,000 | $17.72 | $177,200.00 | |
| 3/5/2015 | William S Marth | CEO | Buy | 20,000 | $17.70 | $354,000.00 | |
| 3/2/2015 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $16.39 | $491,700.00 | |
| 2/10/2015 | Ambra Thomas E Phd D | Director | Sell | 20,000 | $16.91 | $338,200.00 | |
| 2/2/2015 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $16.32 | $489,600.00 | |
| 1/12/2015 | Ambra Thomas E Phd D | Director | Sell | 20,000 | $16.45 | $329,000.00 | |
| 1/7/2015 | Stuart M Cable | Major Shareholder | Sell | 7,694 | $16.00 | $123,104.00 | |
| 1/5/2015 | Stuart M Cable | Major Shareholder | Sell | 22,306 | $16.21 | $361,580.26 | |
| 12/10/2014 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $16.24 | $324,800.00 | |
| 12/5/2014 | Stuart M Cable | Major Shareholder | Sell | 13,307 | $16.00 | $212,912.00 | |
| 12/4/2014 | Stuart M Cable | Major Shareholder | Sell | 16,693 | $16.00 | $267,088.00 | |
| 11/10/2014 | William S Marth | CEO | Buy | 30,000 | $17.01 | $510,300.00 | |
| 10/10/2014 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $21.62 | $432,400.00 | |
| 10/1/2014 | Lori M Henderson | SVP | Sell | 1,000 | $21.48 | $21,480.00 | |
| 10/1/2014 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $21.61 | $648,300.00 | |
| 9/10/2014 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $20.12 | $402,400.00 | |
| 9/2/2014 | Lori M Henderson | SVP | Sell | 2,500 | $19.56 | $48,900.00 | |
| 8/28/2014 | Steven R Hagen | SVP | Sell | 1,250 | $19.74 | $24,675.00 | |
| 8/14/2014 | Michael M Nolan | CFO | Sell | 10,000 | $19.76 | $197,600.00 | |
| 8/12/2014 | Lori M Henderson | SVP | Sell | 30,000 | $19.05 | $571,500.00 | |
| 8/11/2014 | Ambra Thomas E Phd D | Director | Sell | 20,000 | $18.99 | $379,800.00 | |
| 8/8/2014 | Steven R Hagen | SVP | Sell | 10,797 | $18.99 | $205,035.03 | |
| 8/1/2014 | Lori M Henderson | SVP | Sell | 2,500 | $18.56 | $46,400.00 | |
| 8/1/2014 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $18.69 | $560,700.00 | |
| 7/10/2014 | Ambra Thomas E Phd D | Director | Sell | 20,000 | $20.94 | $418,800.00 | |
| 7/1/2014 | Lori M Henderson | SVP | Sell | 2,500 | $20.62 | $51,550.00 | |
| 7/1/2014 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $21.00 | $630,000.00 | |
| 6/3/2014 | Steven R Hagen | SVP | Sell | 2,500 | $16.93 | $42,325.00 | |
| 5/16/2014 | Steven Hagen | SVP | Sell | 1,250 | $15.45 | $19,312.50 | |
| 5/15/2014 | George Svokos | SVP | Buy | 10,000 | $15.60 | $156,000.00 | |
| 5/12/2014 | Steven Hagen | SVP | Sell | 5,897 | $15.00 | $88,455.00 | |
| 5/12/2014 | William Marth | CEO | Buy | 30,000 | $15.40 | $462,000.00 | |
| 5/1/2014 | Lori Henderson | VP | Sell | 2,500 | $15.73 | $39,325.00 | |
| 5/1/2014 | Stuart Cable | major shareholder | Sell | 30,000 | $15.98 | $479,400.00 | |
| 4/1/2014 | Lori Henderson | VP | Sell | 2,500 | $18.74 | $46,850.00 | |
| 4/1/2014 | Stuart Cable | major shareholder | Sell | 30,000 | $18.52 | $555,600.00 | |
| 2/27/2014 | Arthur Roth | Director | Sell | 5,000 | $15.95 | $79,750.00 | |
| 2/27/2014 | Steven Hagen | SVP | Sell | 3,000 | $15.73 | $47,190.00 | |
| 2/25/2014 | Steven Hagen | SVP | Sell | 2,500 | $15.19 | $37,975.00 | |
| 2/24/2014 | Michael Nolan | CFO | Sell | 15,000 | $15.00 | $225,000.00 | |
| 2/21/2014 | Steven Hagen | SVP | Sell | 1,500 | $14.87 | $22,305.00 | |
| 2/19/2014 | Steven Hagen | SVP | Sell | 1,500 | $13.37 | $20,055.00 | |
| 2/13/2014 | Stuart Cable | major shareholder | Sell | 30,000 | $12.00 | $360,000.00 | |
| 12/4/2013 | Steven Hagen | SVP | Sell | 2,500 | $10.93 | $27,325.00 | |
| 12/3/2013 | William Marth | Director | Buy | 30,000 | $10.75 | $322,500.00 | |
| 11/22/2013 | Steven Hagen | SVP | Sell | 2,300 | $11.55 | $26,565.00 | |
| 11/22/2013 | William Marth | Director | Buy | 20,000 | $11.57 | $231,400.00 | |
| 9/13/2013 | Stuart Cable | major shareholder | Sell | 30,000 | $12.00 | $360,000.00 | |
| 8/1/2013 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $12.53 | $375,900.00 | |
| 7/1/2013 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $12.47 | $374,100.00 | |
| 6/12/2013 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $12.00 | $360,000.00 | |
| 5/22/2013 | Bruce J Sargent | SVP | Sell | 7,500 | $10.97 | $82,275.00 | |
| 5/10/2013 | Steven R Hagen | SVP | Sell | 1,200 | $10.40 | $12,480.00 | |
| 12/3/2012 | William S Marth | Director | Buy | 10,000 | $5.00 | $50,000.00 | |
| 11/15/2012 | Ambra Thomas E Phd D | CEO | Buy | 10,000 | $3.80 | $38,000.00 | |
| 8/9/2012 | Steven R Hagen | VP | Sell | 3,000 | $3.00 | $9,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Albany Molecular Research (NASDAQ:AMRI)
Latest Headlines for Albany Molecular Research (NASDAQ:AMRI)
| Source: |
|
Loading headlines, please wait.
Albany Molecular Research (AMRI) Chart for Monday, October, 23, 2017
